"Unifuzol®" in Patients With Peripheral Arterial Disease

Peripheral Arterial Disease Clinical Trial

Official title:

A Multicentre, Randomized, Double-blind, Placebo-controlled Study of the Safety and Efficacy of Unifuzol® in Patients With Peripheral Arterial Disease

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03861416
• Other study ID #: UNI-II-2016
• Status: Completed
• Phase: Phase 2
• Start date: March 16, 2018
• Est. completion date: October 26, 2019

Study information

• Verified date: January 2020
• Source: POLYSAN Scientific & Technological Pharmaceutical Company
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The present study is a multicenter, randomized, double-blind, placebo-controlled study of the safety and efficacy of the drug Unifuzol® (L-arginine) in patients with obliterating atherosclerosis of the lower extremities. The study recruits patients 40-79 years old with a confirmed diagnosis of chronic ischemia of the lower limb and a stable symptom of intermittent claudication that occurs when walking a distance of 100-299 meters. L-arginine improves microcirculation due to activation of nitrogen monoxide production and stimulates capillary blood flow, thus can probably improve the quality of life of patients with intermittent claudication. The criterion for treatment efficacy will be an increase in the maximum walking distance measures before and on the next day after the end of treatment course.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 360
• Est. completion date: October 26, 2019
• Est. primary completion date: September 13, 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 40 Years to 79 Years

Eligibility

Inclusion Criteria:

1. Signed Informed Consent

2. Male and female patients 40-79 years old

3. Patients with atherosclerosis of native arteries of the lower extremity vessels (ICD-10 code: I70.2)

4. Clinical syndrome of chronic lower limb ischemia

5. The symptom of intermittent claudication persisting for 6 months or more (before the start of screening), causing a stable restriction of physical activity to the maximum walking distance 100-299 m

6. The ankle-brachial index (ABI) less than 0.9; in patients with diabetes mellitus ABI >1.2 is acceptable, provided the occlusion of the main arteries of the lower extremities is confirmed

7. Patient consent to the use of adequate methods of contraception or full abstinence from sexual activity for the period of the study and within 30 days after its completion

8. The difference between the maximum walking distance at the second and the first treadmill test at the screening (interval at least 3 days) does not exceed 25% from baseline, i.e. the first treadmill test

9. Patients not receiving drugs for the treatment of atherosclerosis obliterans of the lower extremities or receiving them in constant doses for at least 6 weeks prior to screening.

10. No contraindications for treadmill test

Exclusion Criteria:

1. Intolerance or hypersensitivity to the components of the study drug.

2. Intake of succinic acid, L-arginine, malic acid, fumaric acid, anticoagulants, or hormones (with the exception of insulin) within 6 weeks before the start of screening, or the use of these medications is scheduled within the patient's participation in the study

3. Any severe disease or condition that may make it unsafe and/or impossible for the patient to participate in the study and/or lead to the inability of the patient to comply with the study procedures (including, but not limited to: renal failure, hepatic failure, blood diseases, psychiatric conditions, infections)

4. History of malignancy (with the exception of basal cell skin cancer)

5. Alcohol or drug abuse

6. The presence of clinically significant decompensated cardiovascular diseases (unstable angina or stenocardia of functional class III and above, chronic heart failure III - IV class according to NYHA, uncontrolled arterial hypertension, acute cerebrovascular accident or acute myocardial infarction within 6 months prior to screening, unstable arrhythmias, deep venous thrombosis, stenosis of the internal carotid arteries >70%, aortic aneurysm)

7. Decompensation of the peripheral circulation: rest pain, trophic ulcers, gangrene

8. Any other diseases that affect the assessment of walking distance and limit patient's physical activity

9. The level of glycated hemoglobin (HbA1c) >= 8%

10. Planned reconstructive surgery on the limb vessels within 6 months from screening

11. Amputation on one or both limbs or planned amputation within 6 months from screening

12. Other circumstances impeding patient compliance with the schedule of procedures

13. For patients applying or planning the use of NSAIDs: the inability to cancel the use of NSAIDs 12 hours before the treadmill test.

14. The body mass index >35

15. Contraindications for conducting the treadmill test

16. Heart rate is more than 80% of the maximum frequency (the maximum frequency is defined as 220 - age) at the moment of pain in the legs.

17. Depression of an ST segment or the occurrence of sustained (lasting more than 30 seconds) cardiac rhythm or conduction disturbances during a treadmill test.

18. Drop of systolic blood pressure during the first 5 minutes after the completion of the treadmill test

19. Participation in another clinical study

20. Pregnancy or breastfeeding

21. Any other diseases / conditions in the stage of decompensation

22. Employees of the research center and their family members.

Related Conditions & MeSH terms

• Peripheral Arterial Disease
• Peripheral Vascular Diseases

Intervention

Drug:
• L-arginine 1.4% 500 ml
Infusion of L-arginine 1.4% solution by 500 ml (2 vials 250 ml each) IV daily for 10 days
• L-arginine 1.4% 250 ml + placebo 250 ml
Infusion of L-arginine 1.4% solution 250 ml IV daily for 10 days and placebo infusion by 250 ml IV daily for 10 days.
• Placebo solution
Infusion of Ringer's solution by 500 ml (2 vials 250 ml each) IV daily for 10 days

Locations

Country	Name	City	State
Russian Federation	Regional Clinical Hospital	Barnaul
Russian Federation	Kursk City Clinical Emergency Hospital	Kursk
Russian Federation	City Clinical Hospital ? 15 named O.M. Filatov	Moscow
Russian Federation	Medical and sanitary Department of the Ministry of Internal Affairs of the Russian Federation in Moscow	Moscow
Russian Federation	City Clinical Hospital ?2 of the Novosibirsk Region	Novosibirsk
Russian Federation	National Medical Research Center named after Academician E.N. Meshalkin	Novosibirsk
Russian Federation	State Novosibirsk Regional Clinical Hospital	Novosibirsk
Russian Federation	Multidisciplinary center of modern medicine "Euromed"	Omsk
Russian Federation	Orenburg Regional Clinical Hospital	Orenburg
Russian Federation	Rostov State Medical University	Rostov-on-Don
Russian Federation	Ryazan Regional Clinical Cardiological dispensary	Ryazan
Russian Federation	City General Hospital ?2	Saint Petersburg
Russian Federation	City Hospital ?38 named after N.A. Semashko	Saint Petersburg
Russian Federation	Consultative and diagnostic center No. 85	Saint Petersburg
Russian Federation	Road Clinical Hospital of the Russian Railways Open Joint-Stock Company	Saint Petersburg
Russian Federation	St. Petersburg State Medical University n.a. I.P.Pavlov	Saint Petersburg
Russian Federation	Regional Clinical Cardiology Dispensary	Saratov
Russian Federation	Clinical hospital ?10 of the Yaroslavl region	Yaroslavl
Russian Federation	Regional Clinical Hospital of the Yaroslavl region	Yaroslavl

Sponsors (1)

Lead Sponsor	Collaborator
POLYSAN Scientific & Technological Pharmaceutical Company

Country where clinical trial is conducted

Russian Federation, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Maximum walking distance	The change in the maximum walking distance on the next day (day 11) after the completion of treatment course and on day 30 in comparison with the initial value. The change will be expressed as the ratio of the natural logarithms of the maximum walking distance on day 11 and to the baseline value (day 1).	day 11, day 30